These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 37114781)
21. A Comprehensive Review on DNA Gyrase Inhibitors. Chitra SR; Ramalakshmi N; Arunkumar S; Manimegalai P Infect Disord Drug Targets; 2020; 20(6):765-777. PubMed ID: 33109068 [TBL] [Abstract][Full Text] [Related]
22. Synthesis, antimicrobial, SAR, PASS, molecular docking, molecular dynamics and pharmacokinetics studies of 5'- Munia NS; Hosen MA; Azzam KMA; Al-Ghorbani M; Baashen M; Hossain MK; Ali F; Mahmud S; Shimu MSS; Almalki FA; Hadda TB; Laaroussi H; Naimi S; Kawsar SMA Nucleosides Nucleotides Nucleic Acids; 2022; 41(10):1036-1083. PubMed ID: 35797068 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, in vitro antimicrobial evaluation and molecular docking studies of indol-2-one tagged with morpholinosulfonyl moiety as DNA gyrase inhibitors. Salem MA; Ragab A; El-Khalafawy A; Makhlouf AH; Askar AA; Ammar YA Bioorg Chem; 2020 Mar; 96():103619. PubMed ID: 32036161 [TBL] [Abstract][Full Text] [Related]
24. Identification of chebulinic acid as potent natural inhibitor of M. tuberculosis DNA gyrase and molecular insights into its binding mode of action. Patel K; Tyagi C; Goyal S; Jamal S; Wahi D; Jain R; Bharadvaja N; Grover A Comput Biol Chem; 2015 Dec; 59 Pt A():37-47. PubMed ID: 26410242 [TBL] [Abstract][Full Text] [Related]
25. Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site. Franco-Ulloa S; La Sala G; Miscione GP; De Vivo M Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401640 [TBL] [Abstract][Full Text] [Related]
26. In silico Molecular Docking, DFT Analysis and ADMET Studies of Carbazole Alkaloid and Coumarins from Roots of Eswaramoorthy R; Hailekiros H; Kedir F; Endale M Adv Appl Bioinform Chem; 2021; 14():13-24. PubMed ID: 33584098 [TBL] [Abstract][Full Text] [Related]
27. Synthesis, antimicrobial evaluation, DNA gyrase inhibition, and in silico pharmacokinetic studies of novel quinoline derivatives. El-Shershaby MH; El-Gamal KM; Bayoumi AH; El-Adl K; Ahmed HEA; Abulkhair HS Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000277. PubMed ID: 33078877 [TBL] [Abstract][Full Text] [Related]
28. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. Kashyap A; Singh PK; Satpati S; Verma H; Silakari O J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589 [TBL] [Abstract][Full Text] [Related]
29. Atomistic simulation on flavonoids derivatives as potential inhibitors of bacterial gyrase of Ramachandran B; Srinivasadesikan V; Chou TM; Jeyakanthan J; Lee SL J Biomol Struct Dyn; 2022 Jul; 40(10):4314-4327. PubMed ID: 33308046 [TBL] [Abstract][Full Text] [Related]
30. Computational and Preclinical Prediction of the Antimicrobial Properties of an Agent Isolated from Onikanni SA; Lawal B; Fadaka AO; Bakare O; Adewole E; Taher M; Khotib J; Susanti D; Oyinloye BE; Ajiboye BO; Ojo OA; Sibuyi NRS Molecules; 2023 Feb; 28(4):. PubMed ID: 36838579 [TBL] [Abstract][Full Text] [Related]
31. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation. Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630 [TBL] [Abstract][Full Text] [Related]
32. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis. Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Ostrov DA; Hernández Prada JA; Corsino PE; Finton KA; Le N; Rowe TC Antimicrob Agents Chemother; 2007 Oct; 51(10):3688-98. PubMed ID: 17682095 [TBL] [Abstract][Full Text] [Related]
34. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Eakin AE; Green O; Hales N; Walkup GK; Bist S; Singh A; Mullen G; Bryant J; Embrey K; Gao N; Breeze A; Timms D; Andrews B; Uria-Nickelsen M; Demeritt J; Loch JT; Hull K; Blodgett A; Illingworth RN; Prince B; Boriack-Sjodin PA; Hauck S; MacPherson LJ; Ni H; Sherer B Antimicrob Agents Chemother; 2012 Mar; 56(3):1240-6. PubMed ID: 22183167 [TBL] [Abstract][Full Text] [Related]
35. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV. Metwally NH; Abdallah SO; Mohsen MMA Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481 [TBL] [Abstract][Full Text] [Related]
36. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents. Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509 [TBL] [Abstract][Full Text] [Related]
37. Identification of new DNA gyrase inhibitors based on bioactive compounds from streptomyces: structure-based virtual screening and molecular dynamics simulations approaches. Kalhor H; Sadeghi S; Marashiyan M; Kalhor R; Aghaei Gharehbolagh S; Akbari Eidgahi MR; Rahimi H J Biomol Struct Dyn; 2020 Feb; 38(3):791-806. PubMed ID: 30916622 [TBL] [Abstract][Full Text] [Related]
38. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein. Adeniji SE Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260 [TBL] [Abstract][Full Text] [Related]
39. Novel 2-arylbenzothiazole DNA gyrase inhibitors: Synthesis, antimicrobial evaluation, QSAR and molecular docking studies. Ghannam IAY; Abd El-Meguid EA; Ali IH; Sheir DH; El Kerdawy AM Bioorg Chem; 2019 Dec; 93():103373. PubMed ID: 31698294 [TBL] [Abstract][Full Text] [Related]
40. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]